Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;1871(2):434-454.
doi: 10.1016/j.bbcan.2019.04.005. Epub 2019 Apr 26.

Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer

Patrycja Nowak-Sliwinska  1 , Leonardo Scapozza  2 , Ariel Ruiz i Altaba  3
Affiliations
Review

Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer

Patrycja Nowak-Sliwinska et al. Biochim Biophys Acta Rev Cancer. 2019 Apr.

Abstract

The strategy of using existing drugs originally developed for one disease to treat other indications has found success across medical fields. Such drug repurposing promises faster access of drugs to patients while reducing costs in the long and difficult process of drug development. However, the number of existing drugs and diseases, together with the heterogeneity of patients and diseases, notably including cancers, can make repurposing time consuming and inefficient. The key question we address is how to efficiently repurpose an existing drug to treat a given indication. As drug efficacy remains the main bottleneck for overall success, we discuss the need for machine-learning computational methods in combination with specific phenotypic studies along with mechanistic studies, chemical genetics and omics assays to successfully predict disease-drug pairs. Such a pipeline could be particularly important to cancer patients who face heterogeneous, recurrent and metastatic disease and need fast and personalized treatments. Here we focus on drug repurposing for colorectal cancer and describe selected therapeutics already repositioned for its prevention and/or treatment as well as potential candidates. We consider this review as a selective compilation of approaches and methodologies, and argue how, taken together, they could bring drug repurposing to the next level.

Keywords: Colorectal cancer; Computational approaches; Drug repositioning; Mechanism of action; Omics; On/off-target effects; Phenotypes; Polypharmacology; Repurposing in oncology; Side effects; Signaling pathways.

PubMed Disclaimer

Figures

Scheme 1
Scheme 1
Drug development scheme. A. Traditional drug development. B. Drug candidates with good clinical safety profiles can be repurposed relatively easily when the same, delivery route is used. C. Drug candidates repurposed using different routes than in the original indication require safety clinical testing. D. Repurposed drug combinations, depending on on-target/off-target characterization, might or might not (therefore the question mark) require a clinical safety step to reach clinical efficacy test.
Scheme 2
Scheme 2
Classical drug development pathway and drug repurposing options.
See this image and copyright information in PMC

References

    1. Ashburn T.T., Thor K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 2004;3(8):673–683. - PubMed
    1. Hopkins A.L. Drug discovery: predicting promiscuity. Nature. 2009;462(7270):167–168. - PubMed
    1. Pantziarka P. Scientific advice – is drug repurposing missing a trick? Nat. Rev. Clin. Oncol. 2017;14(8):455–456. - PubMed
    1. Brown A.S., Patel C.J. A standard database for drug repositioning. Sci. Data. 2017;4:170029. - PMC - PubMed
    1. Allison M. NCATS launches drug repurposing program. Nat. Biotechnol. 2012;30(7):571–572. - PubMed

Publication types

Substances